Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

costs and expenses for the 2013 period was primarily attributable to the timing of educational and marketing programs, combined with lower personnel costs for the company's hospital sales specialists. These reductions were partially offset by higher legal expenses incurred during the 2013 period related to the company's intellectual property litigation.

As of March 31, 2013, Cadence held cash, cash equivalents and short-term investments of $64.2 million, an increase of $2.1 million from the $62.1 million at December 31, 2012. Net accounts receivable at March 31, 2013, was $8.9 million.

GuidanceAs of May 2, 2013, Cadence is increasing its guidance to reflect the impact of the deferred revenue recognized in the first quarter of 2013. It now expects that net product revenue from sales of OFIRMEV for the twelve months ending December 31, 2013, will range from approximately $97.0 million to $103.0 million.

Conference Call and Webcast on May 2, 2013 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) Cadence management will host a conference call on May 2, 2013, at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) and interested investors may participate in the conference call by dialing (877) 303-9145 (domestic) or (760) 536-5203 (international). To access the webcast, please visit the company's website at www.cadencepharm.com and go to the Investors page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call. Cadence uses the Investors portion of its website as one means of disclosing material non-public information, and investors are encouraged to monitor Cadence's website in addition to following the company's press releases, SEC filings and public conference calls and webcasts.

About OFIRMEV® (Acetaminophen) InjectionOFIRMEV (acetaminophen) injection (1000 mg / 1
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 1, 2015   Neuraltus Pharmaceuticals, Inc. , a ... groundbreaking drugs to treat neurodegenerative diseases such as ... Robert G. Miller , M.D., Director of the Forbes ... Pacific Medical Center in San Francisco, has been awarded ... million to help fund a Phase 2 clinical ...
(Date:7/1/2015)... InferMed , s decision ... augment Elsevier ... suite   Elsevier , a world-leading provider ... today the acquisition of  InferMed , a London ... InferMed,s Arezzo technology supports clinicians in choosing the most appropriate ...
(Date:6/30/2015)... , July 1, 2015 R-Japan Co.,Ltd. obtained ... the Safety of Regenerative Medicine from the Ministry of Health, ... June 29, 2015. The fact that R- ... facility through the auditing from Pharmaceuticals and Medical Devices Agency ... application, allows it to provide stem cell manufacturing service to ...
(Date:6/30/2015)... 30, 2015  NASA astronaut Kjell Lindgren , who ... his first mission to the International Space Station , ... 9 a.m. EDT Tuesday, July 7. Lindgren will ... Russia . The interviews will be preceded ... his mission training. To schedule an interview, media ...
Breaking Biology Technology:Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2
... June 10 Campbell Alliance, the leading,management consulting ... announced that executives from the firm,s Trade and,Distribution ... Intelligence,(CBI) 4th Annual Commercial Contracts and Chargeback Management ... 19-20, 2008, at,the Hyatt Regency Philadelphia at Penn,s ...
... June 10 Premier Research Group plc, the,international ... announced management buyout. As a result, the company ... the London Stock Exchange. The UK-based,private equity firm ... Said Dr. Simon Yaxley, Chief Executive Officer of ...
... AngioGenex Inc. (OTC,Bulletin Board: AGGX.OB) a New ... of Id targeted anti-angiogenic drugs, announced the,appointment of ... Garland,formerly with Hoffmann La Roche, Inc., has directed ... stage biotech companies such as,Centaur Pharmaceuticals, Atairgin Technologies, ...
Cached Biology Technology:Campbell Alliance Trade and Distribution Practice to Speak at CBI's Commercial Contracts and Chargeback Management Conference 2Campbell Alliance Trade and Distribution Practice to Speak at CBI's Commercial Contracts and Chargeback Management Conference 3Premier Research Announces Completion of Management Buyout 2AngioGenex Appoints New CEO to Direct Development of Anti-Cancer Drugs 2AngioGenex Appoints New CEO to Direct Development of Anti-Cancer Drugs 3
(Date:6/25/2015)... June 25, 2015 According ... Type (Swipe & Area), Technology, Material (Optical Prism, ... Commercial Security & Others) & Geography - Global ... the said market is expected to reach $14,500.07 ... Browse 76 market Tables and ...
(Date:6/24/2015)... , June 24, 2015 This report provides ... the next six years. It contains an analysis of ... along with their impact from the short, medium, and ... discusses the industry, market, and technology trends that currently, ... need of concerned authorities to efficiently manage the increasing ...
(Date:6/23/2015)... MINNETONKA, Minn. , June 23, 2015 /PRNewswire/ ... technology company that supports the entire spectrum of ... iMedNet ™ , the company,s ... has been awarded a Silver 2015 Stevie® Award ... the Health Products & Services Website category.  The ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2
... vascular targeting agent completely prevented the development of bone ... a preclinical study, providing early evidence that it could ... common destination for a number of cancers when they ... Texas M. D. Anderson Cancer Center reported in the ...
... LSU's Museum of Natural Science, or LSUMNS, and adjunct ... of lizard while conducting field research in Borneo. ... Institute of Biodiversity and Environmental Conservation at the Universiti ... the new species in the prestigious Journal of Herpetology. ...
... of the soul," corneas are the panes in those windows. ... act as the eye's outermost lens, contributing up to 75 ... San Francisco at the annual meeting of the American Chemical ... biomimetic material that's finding its way into artificial corneas. It's ...
Cached Biology News:'Trojan Horse' agent halts bone metastasis in mice 2'Trojan Horse' agent halts bone metastasis in mice 3LSU professor discovers new species 2An artificial cornea is in sight, thanks to biomimetic hydrogels 2An artificial cornea is in sight, thanks to biomimetic hydrogels 3An artificial cornea is in sight, thanks to biomimetic hydrogels 4
... (5-bromo-4-chloro-3-indoyl-beta-D-galactopyranoside) is a chromogenic ... recombinant plasmids. In the ... IPTG, lac + ... whereas recombinant colonies appear ...
... fully flexible quadrupole MS detector optimized for ... 1-D and 2-D LC, as well as ... a drying gas system to create a ... for low-to-medium polarity compounds, while providing for ...
... PsiPort Mass Directed Auto Purification software, ... acquisition system designed for automated compound ... science and pharmaceutical discovery programs. The ... simplify high throughput mass directed auto ...
Miniature FRENCH Pressure Cell with 3.7ml capacity; pressure up to 20,000 psi....
Biology Products: